A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s Disease
Figure 2
BV2 microglial cells were pretreated with DHB for 1 h followed by co-treatment with LPS (100 ng/mL) for 16 h. ROS levels were measured using the DCFDA method. * compared with the control group, ** compared with the LPS-treated group.